Formycon AG (FYB.DE)
EUR 53.4
(2.5%)
EUR 53.4
(2.5%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -369 Thousand EUR | 97.59% |
| 2022 | -17.72 Million EUR | -28.2% |
| 2021 | -13.82 Million EUR | -140.95% |
| 2020 | -5.73 Million EUR | -152.7% |
| 2019 | -2.27 Million EUR | -131.9% |
| 2018 | 7.11 Million EUR | 554.03% |
| 2017 | -1.56 Million EUR | 61.22% |
| 2016 | -4.04 Million EUR | -708.05% |
| 2015 | 665.01 Thousand EUR | -23.63% |
| 2014 | 870.79 Thousand EUR | 111.26% |
| 2013 | -7.73 Million EUR | -236.95% |
| 2012 | -2.29 Million EUR | -78.54% |
| 2011 | -1.28 Million EUR | -26.14% |
| 2010 | -1.01 Million EUR | -433.82% |
| 2009 | -191 Thousand EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -17.98 Million EUR | 0.0% |
| 2023 Q2 | 6.48 Million EUR | 0.0% |
| 2023 Q4 | -6.91 Million EUR | 0.0% |
| 2023 FY | -428 Thousand EUR | 97.59% |
| 2022 FY | -17.72 Million EUR | -28.2% |
| 2022 Q2 | -8.35 Million EUR | 0.0% |
| 2022 Q4 | -9.37 Million EUR | 0.0% |
| 2021 Q2 | -10.16 Million EUR | 0.0% |
| 2021 Q4 | -7.81 Million EUR | 0.0% |
| 2021 FY | -13.82 Million EUR | -140.95% |
| 2020 Q4 | -4.4 Million EUR | 0.0% |
| 2020 FY | -5.73 Million EUR | -152.7% |
| 2020 Q2 | -1.33 Million EUR | 0.0% |
| 2019 Q2 | -691.49 Thousand EUR | 0.0% |
| 2019 FY | -2.27 Million EUR | -131.9% |
| 2019 Q4 | -1.57 Million EUR | 0.0% |
| 2018 Q4 | -1.08 Million EUR | 0.0% |
| 2018 Q2 | 8.2 Million EUR | 0.0% |
| 2018 FY | 7.11 Million EUR | 554.03% |
| 2017 Q4 | 1.32 Million EUR | 0.0% |
| 2017 FY | -1.56 Million EUR | 61.22% |
| 2017 Q2 | -2.89 Million EUR | 0.0% |
| 2016 FY | -4.04 Million EUR | -708.05% |
| 2016 Q2 | -1.15 Million EUR | 0.0% |
| 2016 Q4 | -2.88 Million EUR | 0.0% |
| 2015 Q4 | -862.25 Thousand EUR | 0.0% |
| 2015 Q2 | 1.52 Million EUR | 0.0% |
| 2015 FY | 665.01 Thousand EUR | -23.63% |
| 2014 FY | 870.79 Thousand EUR | 111.26% |
| 2014 Q4 | -1.87 Million EUR | 0.0% |
| 2014 Q2 | 2.74 Million EUR | 0.0% |
| 2013 Q3 | -1.93 Million EUR | 0.0% |
| 2013 FY | -7.73 Million EUR | -236.95% |
| 2013 Q4 | 217.37 Thousand EUR | 111.24% |
| 2013 Q2 | -1.93 Million EUR | 0.0% |
| 2013 Q1 | -1.93 Million EUR | 0.0% |
| 2012 Q3 | -592.35 Thousand EUR | 0.0% |
| 2012 Q1 | -592.35 Thousand EUR | 0.0% |
| 2012 Q4 | -1.93 Million EUR | -226.53% |
| 2012 Q2 | -592.35 Thousand EUR | 0.0% |
| 2012 FY | -2.29 Million EUR | -78.54% |
| 2011 Q2 | -321.25 Thousand EUR | 0.0% |
| 2011 Q1 | -321.25 Thousand EUR | 0.0% |
| 2011 FY | -1.28 Million EUR | -26.14% |
| 2011 Q3 | -321.25 Thousand EUR | 0.0% |
| 2011 Q4 | -592.35 Thousand EUR | -84.39% |
| 2010 Q1 | -252.08 Thousand EUR | 0.0% |
| 2010 FY | -1.01 Million EUR | -433.82% |
| 2010 Q4 | -321.25 Thousand EUR | -27.44% |
| 2010 Q3 | -252.08 Thousand EUR | 0.0% |
| 2010 Q2 | -252.08 Thousand EUR | 0.0% |
| 2009 Q4 | -252.08 Thousand EUR | -427.92% |
| 2009 Q2 | -47.75 Thousand EUR | 0.0% |
| 2009 Q1 | -47.75 Thousand EUR | 0.0% |
| 2009 Q3 | -47.75 Thousand EUR | 0.0% |
| 2009 FY | -191 Thousand EUR | 0.0% |
| 2008 Q4 | -47.75 Thousand EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| BioNTech SE | 690.4 Million EUR | 100.053% |
| CureVac N.V. | -274.2 Million EUR | 99.865% |
| Biotest Aktiengesellschaft | 143.5 Million EUR | 100.257% |
| Biotest Aktiengesellschaft | 143.5 Million EUR | 100.257% |
| BRAIN Biotech AG | -6.71 Million EUR | 94.505% |
| Heidelberg Pharma AG | -21.2 Million EUR | 98.26% |
| Medigene AG | -16.14 Million EUR | 97.715% |